Dexrazoxane and Oncovin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dexrazoxane (dexrazoxane hydrochloride) and Oncovin (vincristine sulfate). Common drug interactions include cerebral infarction among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Dexrazoxane and Oncovin. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Dexrazoxane?

Dexrazoxane has active ingredients of dexrazoxane hydrochloride. eHealthMe is studying from 1,141 Dexrazoxane users. Check the latest studies of Dexrazoxane.

What is Oncovin?

Oncovin has active ingredients of vincristine sulfate. eHealthMe is studying from 6,667 Oncovin users. Check the latest studies of Oncovin.

On Aug, 10, 2026

40 people who take Dexrazoxane and Oncovin together, and have interactions are studied.

Dexrazoxane and Oncovin drug interactions.

What are the common drug interactions of Dexrazoxane and Oncovin, by gender? *:

female:

Cerebral infarction (less blood supply to brain resulting tissue damage)
Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
Intracranial venous sinus thrombosis (presence of thrombosis (a blood clot) in the dural venous sinuses, which drain blood from the brain)
Phlebitis (inflammation of the walls of a vein)

male:

Neutropenia (an abnormally low number of neutrophils)
Renal impairment (severely reduced kidney function)
Epstein-barr virus associated lymphoproliferative disorder (lymphocytes are produced in excessive quantities associated with epstein-barr virus)
Malaise (a feeling of general discomfort or uneasiness)
Neuropathy peripheral (surface nerve damage)
Pyrexia (fever)
Thrombocytopenia (decrease of platelets in blood)
Vomiting
Alanine aminotransferase increased
Antithrombin iii decreased

What are the common drug interactions of Dexrazoxane and Oncovin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Neutropenia (an abnormally low number of neutrophils)
Renal impairment (severely reduced kidney function)
Epstein-barr viraemia
Lymphoproliferative disorder (a medical condition in which the immune system makes too many white blood cells)
Burkitt's lymphoma stage iii (blood cancer stage iii)
Epstein-barr virus associated lymphoproliferative disorder (lymphocytes are produced in excessive quantities associated with epstein-barr virus)
Weight decreased

20-29:

Cerebral infarction (less blood supply to brain resulting tissue damage)
Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
Intracranial venous sinus thrombosis (presence of thrombosis (a blood clot) in the dural venous sinuses, which drain blood from the brain)
Phlebitis (inflammation of the walls of a vein)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Myelosuppression (a decrease in the production of blood cells)
Nausea (feeling of having an urge to vomit)
Vomiting
Alanine aminotransferase increased
Antithrombin iii decreased
Constipation
Urinary retention (the inability to completely or partially empty the bladder)
Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Dyspnoea (difficult or laboured respiration)

What are the existing conditions these people have? *

Immunodeficiency Disorders: 31 people, 77.50%
Burkitt's Lymphoma (cancer of the lymphatic system): 31 people, 77.50%
Ill-Defined Disorder: 7 people, 17.50%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 4 people, 10.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 5.00%
Nausea And Vomiting: 2 people, 5.00%
Lymphoma (cancer that begins in immune system cells): 2 people, 5.00%
Insomnia (sleeplessness): 2 people, 5.00%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 2 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dexrazoxane and Oncovin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously